Radioguided sentinel lymph node dissection in patients with localised prostate carcinoma: influence of the dose of radiolabelled colloid to avoid failure of the procedure
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The purpose of this study was to determine the role of the injected dose of tracer in the non-detection of pelvic sentinel lymph nodes (SLN) in patients with prostate carcinoma.
Data were evaluated from 100 patients (age range 43–77, mean 63 years). The first 72 patients (group 1) received 2 × 0.3 ml of 30 MBq-nanocolloid-99 mTc and the remaining 28 patients (group 2) received 2 × 0.3 ml of 100 MBq. Surgery consisted of the detection and dissection of lymph nodes identified as sentinel nodes, followed by an extended lymphadenectomy.
SLNs were located in the interiliac group in 54.2% of patients, in the obturator fossa in 30.7%, in the external iliac group in 10.9% and in the common iliac group in 4.2% of cases. Lymph node involvement was observed in 12% of patients. But there was a 30.6% (22/72) failure rate of the SLN procedure in group 1 and 7.1% (2/28) in group 2. An increased risk of unsuccessful SLN procedure was statistically associated with the low dose of MBq-nanocolloids (p < 0.017). Statistical correlation is also found after the exclusion of the first 30 patients from the study (learning phase of the team) (p < 0.034). None of the other parameters showed a statistical association (age, p < 0.9; Gleason score, p < 0.3; grade pT, p < 0.7). A higher grade or a greater extension of cancer inside the prostate are not responsible for the failure of the SLN procedure.
It seems necessary to inject at least 200 MBq inside the prostate to avoid a failed SLN procedure.
- El-Galley RE, Keane TE, Petros JA, Sanders WH, Clarke HS, Cotsonis GA, et al. Evaluation of staging lymphadenectomy in prostate cancer. Urology 1998;52:663–667. CrossRef
- Haese A, Epstein JI, Huland H, Partin AW. Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma. Cancer 2002;95:1016–1021. CrossRef
- Häcker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006;176:2014–2019. CrossRef
- Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, Hulsbergen van de Kaa C, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491–2499. CrossRef
- Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. J Urol 2007;177:916–920. CrossRef
- American Joint Committee on Cancer. Cancer staging handbook: TNM classification of malignant tumors, 6th edn. Berlin Heidelberg New York: Springer; 2002.
- Gandwindt U, Paulsen F, Corvin S, Hundt I, Alber M, Frey B, et al. Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. Int J Rad Oncol Biol Phys 2007;67:347–355.
- Beri A, Janetschek G. Technology insight: radioguided sentinel lymph node dissection in the staging of prostate cancer. Nature Clin Pract Urol 2006;3:602–610. CrossRef
- Corvin S, Schilling D, Eichhorn K, Hundt I, Hennenlotter J, Anastasiadis AG, et al. Laparoscopic sentinel lymph node dissection—a novel technique for the staging of prostate cancer. Eur Urol 2006;49:280–285. CrossRef
- Corvin S, Schilling D, Anastasiadis AG, Bares R, Stenzl A, Kuczyk M. Radioisotope guided pelvic lymph node dissection for prostate cancer staging. Eur Urol Suppl 2005;4:25–27. CrossRef
- Jeschke S, Nambirajan T, Leeb K, Ziegerhofer J, Sega W, Janetschek G. Detection of early lymph node metastases in prostate cancer by laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2005;173:1943–1946. CrossRef
- Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of ≤10 ng/ml and biopsy Gleason score of ≤6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 2006;97:1173–1178. CrossRef
- Krengli M, Ballarè A, Cannillo A, Rudoni M, Kocjancic E, Gianfranco L, et al. Potential advantage of studying the lymphatic drainage by sentinel node technique and SPECT-CT image fusion for pelvic irradiation of prostate cancer. Int J Rad Oncol Biol Phys 2006;66:1100–1104.
- Takashima H, Egawa M, Imao T, Fukuda M, Yokoyama K, Namiki M. Validity of sentinel lymph node concept for patients with prostate cancer. J Urol 2004;171:2268–2271. CrossRef
- Warncke SH, Mattei A, Fuechsel F, Z’Brun S, Krause T, Studer UE. Detection rate and operating time required for γ probe guided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imaging. Eur Urol 2007;52:126–133. CrossRef
- Weckermann D, Dorn R, Holl G, Wagner T, Harzmann R. Limitations of radioguided surgery in high-risk prostate cancer. Eur Urol 2007;51:1549–1558. CrossRef
- Weckermann D, Wawroschek F, Harzmann R. Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy? Eur Urol 2005;47:45–51. CrossRef
- Wawroschek F, Wagner T, Hamm M, Weckermann D, Vogt H, Märkl B, et al. The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 2003;43(2):132–137. CrossRef
- Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R. Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 2001;166(5):1715–1719. CrossRef
- Wawroschek F, Vogt H, Wengenmair H, Weckermann D, Hamm M, Keil M, et al. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003;70(4):303–310. CrossRef
- Brenot-Rossi I, Bastide C, Garcia S, Dumas S, Esterni B, Pasquier J, et al. Limited pelvic lymphadenectomy using the sentinel lymph node procedure in patients with localised prostate carcinoma: a pilot study. Eur J Nucl Med Mol Imaging 2005;32:635–640. CrossRef
- Brenot-Rossi I, Houvenaeghel G, Jaquemier J, Bardou VJ, Martino M, Hassan-Sebbag N, et al. Nonvisualization of axillary sentinel node during lymphoscintigraphy: is there a pathologic significance in breast cancer? J Nucl Med 2003;44:1232–1237.
- Schwartz GF, Giuliano AE, Veronesi U; Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer 2002;94:2542–2551. CrossRef
- Alazraki N, Glass EC, Castronovo F, Valdés Olmos RA, Podoloff D. Procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness 1.0. J Nucl Med 2002;43:1414–1418.
- Eshima D, Fauconnier T, Eshima L, Thornback JR. Radiopharmaceuticals for lymphoscintigraphy: including dosimetry and radiation considerations. Semin Nucl Med 2000;30:25–32. CrossRef
- Wengenmair H, Kopp J, Wawroscheck F, Grober S, Dorn R, Heidenreich P. Pelvic lymph node diagnosis in prostatic carcinoma: biokinetics and dosimetry of 99mTc-nanocolloid after intraprostatic injection. Nuklearmedizin 2002;41:102–107.
- Radioguided sentinel lymph node dissection in patients with localised prostate carcinoma: influence of the dose of radiolabelled colloid to avoid failure of the procedure
European Journal of Nuclear Medicine and Molecular Imaging
Volume 35, Issue 1 , pp 32-38
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Sentinel node
- Prostate cancer
- Sentinel lymph node
- Prostate carcinoma
- Industry Sectors
- Author Affiliations
- 1. Department of Nuclear Medicine, Institut Paoli-Calmettes, Regional Cancer Center, Université de la Méditerranée, 232 Bd. Sainte Marguerite, 13273, Marseille Cedex 9, France
- 2. Department of Urology, Hospital of the University of Marseille, CHU Nord, Université de la Méditerranée, Marseille, France
- 3. Department of Statistics, Institut Paoli-Calmettes, Regional Cancer Center, Université de la Méditerranée, Marseille, France
- 4. Department of Radiology, Institut Paoli-Calmettes, Regional Cancer Center, Université de la Méditerranée, Marseille, France